Actively Recruiting
18F-Pentixafor PET in Hematologic Malignancies
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-14
100
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
CONDITIONS
Official Title
18F-Pentixafor PET in Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age of 18-80 years old, both sexes, with behavioral capacity
- Patients with suspected or confirmed hematological malignancies
- 18F-FDG PET or other imaging examinations performed according to the treatment plan
- For suspected patients, biopsy or needle biopsy expected to obtain pathological results
- Able to provide informed consent and comply with study requirements
You will not qualify if you...
- Pregnant and lactating women
- Patients with fear or radiophobia, mental disorder, or primary affective disorder
- Received ionizing radiation exceeding 50 mSv annually outside this study within the past year
- Received investigational drugs or devices with uncertain safety or efficacy within 1 month
- Any condition where study participation may cause harm as judged by study chairpersons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
Research Team
P
Peipei Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here